Recent Quotes (30 days)

You have no recent quotes
chg | %

Aurinia Pharmaceuticals Inc  

(Public, TSE:AUP)   Watch this stock  
Find more results for TSE:ISA
7.87
+0.28 (3.69%)
Sep 20 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 7.62 - 7.95
52 week 2.75 - 14.17
Open 7.62
Vol / Avg. 47,405.00/42,484.00
Mkt cap 657.42M
P/E     -
Div/yield     -
EPS -1.67
Shares 83.54M
Beta 3.31
Inst. own     -
Oct 20, 2017
Aurinia Pharmaceuticals Inc. - Special Call - 8:00AM EDT - Add to calendar
Sep 27, 2017
Aurinia Pharmaceuticals Inc at Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology - 8:00AM EDT - Add to calendar
Sep 26, 2017
Aurinia Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference - 10:55AM EDT - Add to calendar
Sep 11, 2017
Aurinia Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference
  

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -729.18% -13465.32%
Operating margin -3054.41% -13187.28%
EBITD margin - -12332.37%
Return on average assets -4.50% -51.44%
Return on average equity -5.48% -83.33%
Employees 20 -
CDP Score - -

Address

1203-4464 Markham St
VICTORIA, BC V8Z 7X8
Canada
+1-250-7442487 (Phone)
+1-250-7442498 (Fax)

Website links

Description

Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company's primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN.

Officers and directors

Richard M. Glickman LL.D. Executive Chairman of the Board, Chief Executive Officer
Age: 57
Dennis Bourgeault Chief Financial Officer, Corporate Secretary
Michael R. Martin Chief Operating Officer
Neil Solomons M.D. Chief Marketing Officer
Celia Economides Associate Vice President, Corporate Communications & Patient Advocacy
Robert B. Huizinga Vice President - Clinical Affairs
Lawrence D. Mandt Vice President - Regulatory and Quality
Age: 57
George M. Milne Jr., Ph.D. Director
Age: 73
Lorin Jeffry Randall Director
Age: 70
Benjamin Rovinski Ph.D. Independent Director
Age: 58